Recent Review Articles – Influenza Vaccines

 Williams JH, Dawson A. Prioritising access to pandemic influenza vaccine: a review of the ethics literature. Version 2. BMC Med Ethics. 2020 May 14;21(1):40. Full Text  

2015 - June 2020

Ainslie KEC, Haber M, Orenstein WA. Challenges in estimating influenza vaccine effectiveness. Expert Rev Vaccines. 2019 May 31:1-14. Abstract

Al-Halifa S. et al. Nanoparticle-Based Vaccines Against Respiratory Viruses. Front Immunol. 2019 Jan 24;10:22. Full text

Angeletti D, Yewdell JW. Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Outflanking Antibody Immunodominance on the Road to Universal Influenza Vaccination. Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7). pii: a028852. Full text

Balasingam S, Wilder-Smith A. Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies. Int J Infect Dis. 2016 May 18. pii: S1201-9712(16)31056-6. Full text

Bandell AR, Simões EA. Live attenuated influenza vaccine tetravalent: a clinical review. Expert Rev Vaccines. 2015 Apr 11:1-11. Abstract

Barr IG. et al. Cell culture-derived influenza vaccines in the severe 2017-2018 epidemic season: a step towards improved influenza vaccine effectiveness. (Australia) NPJ Vaccines. 2018 Oct 9;3:44. Full text

Bartoszko JJ. et al. Does consecutive influenza vaccination reduce protection against influenza: A systematic review and meta-analysis. Vaccine. 2018 Jun 7;36(24):3434-3444. Abstract

Belongia EA. et al. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines. 2017 Jul;16(7):1-14 Abstract

Belongia EA. et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016 Apr 6. pii: S1473-3099(16)00129-8. Abstract

Bhatnagar S, Dave K, Venuganti VVK. Microneedles in the clinic. J Control Release. 2017 May 23. pii: S0168-3659(17)30603-X. Abstract

Black S. Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults. Vaccine. 2015 Jun 8;33 Suppl 2:B3-B5. Full text

Blanco-Lobo P. et al. Novel Approaches for The Development of Live Attenuated Influenza Vaccines. Viruses. 2019 Feb 22;11(2). pii: E190.  Full text

Boudreau CM, Alter G. Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine. Front Immunol. 2019 Mar 18;10:440. Full text

Bouvier NM. The Future of Influenza Vaccines: A Historical and Clinical Perspective. Vaccines (Basel). 2018 Aug 30;6(3). Full text 

Buchy P, Badur S. Who and when to vaccinate against influenza. Int J Infect Dis. 2020 Apr;93:375-387. Full text

Cao JQ, Li JX, Zhu FC. [Research on the main factors influencing influenza vaccine effectiveness]. Zhonghua Yu Fang Yi Xue Za Zhi. 2020 Apr 6;54(4):444-450. Abstract

Chen YC, et al. Adjuvanted-influenza vaccination in patients infected with HIV: A systematic review and meta-analysis of immunogenicity and safety.  Hum Vaccin Immunother. 2019 Sep 30. Full text

Chen JR, et al.  Better influenza vaccines: an industry perspective.  J Biomed Sci. 2020 Feb 14;27(1):33. Full text

 Cho A, Wrammert J. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine. Curr Opin Virol. 2016 Mar 28;17:110-115. Abstract

Chua SCJH, et al.  Alternative Experimental Models for Studying Influenza Proteins, Host-Virus Interactions and Anti-Influenza Drugs.  Pharmaceuticals (Basel). 2019 Sep 30;12(4). pii: E147. Full text

 Clemens EB, Petrie JG, Gordon A.  Epidemiological Studies to Support the Development of Next Generation Influenza Vaccines. Vaccines (Basel). 2018 Mar 26;6(2). pii: E17. Full text

Clemens. EB. et al. Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine. (Australia) Vaccines (Basel). 2018 Mar 26;6(2). pii: E18. Full text

Cobey S, Hensley SE. Immune history and influenza virus susceptibility. Curr Opin Virol. 2017 Jan 12;22:105-111. Abstract

Cohet C. et al. Safety of AS03-adjuvanted influenza vaccines: A review of the evidence. Vaccine. 2019 Apr 25. pii: S0264-410X(19)30522-5. Full text

Costantino V, Trent M, MacIntyre CR.  Modelling of optimal timing for influenza vaccination as a function of intraseasonal waning of immunity and vaccine coverage.  Vaccine. 2019 Oct 16;37(44):6768-6775.  Full Text

Coughlan L, Palese P. Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine. Cell Host Microbe. 2018 Jul 11;24(1):18-24. Abstract

Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2018 Feb 1;2:CD001269. Abstract

Deng L, Wang BZ. A Perspective on Nanoparticle Universal Influenza Vaccines. ACS Infect Dis. 2018 Nov 15. Abstract

Devarajan P. et al. New Insights into the Generation of CD4 Memory May Shape Future Vaccine Strategies for Influenza. Front Immunol. 2016 Apr 11;7:136. Full text

de Vries RD, Rimmelzwaan GF. Viral vector-based influenza vaccines. Hum Vaccin Immunother. 2016 Jul 25:0. Abstract

de Vries RD. et al. Universal influenza vaccines: a realistic option? Clin Microbiol Infect. 2016 Apr 26. pii: S1198-743X(15)01031-9. Abstract

de Vries RD, Altenburg AF, Rimmelzwaan GF. Universal influenza vaccines, science fiction or soon reality? Expert Rev Vaccines. 2015 Jun 23:1-3. Abstract

Elbahesh H. et al. Broadly protective influenza vaccines: design and production platforms. Curr Opin Virol. 2018 Nov 26;34:1-9. Abstract

Estrada LD, Schultz-Cherry S. Development of a Universal Influenza Vaccine. J Immunol. 2019 Jan 15;202(2):392-398. Abstract

Feng S. et al. Estimating Influenza Vaccine Effectiveness With the Test-Negative Design Using Alternative Control Groups: A Systematic Review and Meta-Analysis. Am J Epidemiol. 2018 Feb 1;187(2):389-397. Abstract

Fielding JE. Influenza vaccine effectiveness using the test-negative design: comparability and methodological challenges in meta-analyses. (Australia) Lancet Respir Med. 2017 Mar;5(3):161-162. Abstract

Gou X, et al.  A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine.  Hum Vaccin Immunother. 2019 Aug 23:1-9. Full text

Harding AT, Heaton NS. Efforts to Improve the Seasonal Influenza Vaccine. Vaccines (Basel). 2018 Mar 30;6(2). pii: E19. Full text

Haugh M. et al. A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries. Expert Rev Vaccines. 2017 Jun;16(6):545-564.

Hauser MI. et al. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines.  Vaccine. 2019 Jul 18;37(31):4246-4255. Full Text

Houser K1, Subbarao K. Influenza Vaccines: Challenges and Solutions. Cell Host Microbe. 2015 Mar 11;17(3):295-300 Abstract

Huang C, et al.  Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents.  Vaccine. 2020 Feb 5;38(6):1332-1344. Full text

Hung IFN, Yuen KY. Immunogenicity, safety and tolerability of intradermal influenza vaccines. Hum Vaccin Immunother. 2017 Jun 12:0. Abstract

Isakova-Sivak I, Rudenko L. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines. Expert Rev Vaccines. 2015 Aug 6:1-17. 2015   Abstract

Jazayeri SD, Poh CL.  Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins.  Vaccines (Basel). 2019 Nov 1;7(4). pii: E169.  Read More

Khalaj-Hedayati A, Chua CLL, Smooker P, Lee KW.  Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement.  Influenza Other Respir Viruses. 2019 Nov 27. Read More

Khalaj-Hedayati A, et al.  Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement.  Influenza Other Respir Viruses. 2020 Jan;14(1):92-101. Full text

Kolpe A. et al. M2-based influenza vaccines: recent advances and clinical potential. Expert Rev Vaccines. 2016 Sep 22.  Abstract

Krammer F. Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Biotechnol J. 2015 May;10(5):690-701. Abstract

Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov. 2015 Feb 27;14(3):167-82. Abstract

Kuritzky LA, Pratt M. Systemic Allergic Contact Dermatitis After Formaldehyde-Containing Influenza Vaccination. J Cutan Med Surg. 2015 Apr 15. pii: 1203475415582306 Abstract

Lai JJ. et al. Alternative-Dose versus Standard-Dose Trivalent Influenza Vaccines for Immunocompromised Patients: A Meta-Analysis of Randomised Control Trials. J Clin Med. 2019 Apr 29;8(5). pii: E590. Abstract

Lamb YN.  Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine.  A Review in the Prevention of Influenza.  Drugs. 2019 Aug;79(12):1337-1348. Full text

Lambach P. et al. Considerations of strategies to provide influenza vaccine year round. Vaccine. 2015 Aug 28. pii: S0264-410X(15)01164-0. Full text

Lee LYY, Izzard L, Hurt AC. A Review of DNA Vaccines Against Influenza. Front Immunol. 2018 Jul 9;9:1568. Full text

Leung VK. et al. Concordance of interim and final estimates of influenza vaccine effectiveness: a systematic review. Euro Surveill. 2016 Apr 21;21(16). Abstract

Lin YJ. et al. Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis. Sci Rep. 2018 Jul 30;8(1):11460. Full text

Madelain V, et al.  Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials.  CPT Pharmacometrics Syst Pharmacol. 2020 Mar 20. Full text

Manceur AP, Kamen AA. Critical review of current and emerging quantification methods for the development of influenza vaccine candidates. Vaccine. 2015 Aug 10. pii: S0264-410X(15)01108-1. Abstract

Manini I. et al. Egg-Independent Influenza Vaccines and Vaccine Candidates. Vaccines (Basel). 2017 Jul 18;5(3). pii: E18. Full text

Mathew NR, Angeletti D.  Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance.  Front Immunol. 2020 Jan 10;10:2997. Full text

Martín Arias LH. et al. Guillain-Barré syndrome and influenza vaccines: A meta-analysis. Vaccine. 2015 May 18. pii: S0264-410X(15)00634-9. Abstract

Milián E, Kamen AA. Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines. Biomed Res Int. 2015;2015:504831. Full text 

Morimoto N, Takeishi K. Change in the efficacy of influenza vaccination after repeated inoculation under antigenic mismatch: A systematic review and meta-analysis. Vaccine. 2018 Feb 8;36(7):949-957. Abstract

Nachbagauer R, Krammer F. Universal influenza virus vaccines and therapeutic antibodies. Clin Microbiol Infect. 2017 Feb 12. pii: S1198-743X(17)30097-6.  Abstract

Nachbagauer R, Palese P. Development of next generation hemagglutinin-based broadly protective influenza virus vaccines. Curr Opin Immunol. 2018 Apr 19;53:51-57.  Abstract

Neu KE. et al. Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? Curr Opin Immunol. 2016 Jun 3;42:48-55. Abstract

Nogales A, Martínez-Sobrido L. Reverse Genetics Approaches for the Development of Influenza Vaccines. Int J Mol Sci. 2016 Dec 22;18(1). pii: E20. Full text

Ostrowsky J, et al. Tracking progress in universal influenza vaccine development. Curr Opin Virol. 2020 Apr 9;40:28-36. Full text

Rajão DS, Pérez DR. Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture. Front Microbiol. 2018 Feb 6;9:123. Full text

Ramsay LC. et al. The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis. BMC Med. 2019 Jan 10;17(1):9. Full text

Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines. 2013 May;12(5):519-36. doi: 10.1586/erv.13.35. Abstract

Remschmidt C, Wichmann O, Harder T. Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review. BMC Infect Dis. 2015 Oct 17;15:429.   Full text

Remschmidt C., Wichmann O., Harder T. Methodological quality of systematic reviews on influenza vaccination. Vaccine. 2014 Feb 7. pii: S0264-410X(14)00112-1. Abstract

Ren H, Zhou P. Epitope-focused vaccine design against influenza A and B viruses. Curr Opin Immunol. 2016 Jun 22;42:83-90. Abstract

Ren J., et al. Meta analysis on the immunogenicity of domestic influenza virus vaccines. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.2013 Sep;29(9):981-5. [Article in Chinese] Abstract

Reneer ZB, Ross TM. H2 influenza viruses: designing vaccines against future H2 pandemics. Biochem Soc Trans. 2019 Jan 15. pii: BST20180602. Abstract

Robertson CA. et al. Fluzone® High-Dose Influenza Vaccine. Expert Rev Vaccines. 2016 Dec;15(12):1495-1505. Epub 2016 Nov 14. Abstract

Rose MA, Zielen S, Baumann U. Mucosal immunity and nasal influenza vaccination. Expert Rev Vaccines. 2012 May;11(5):595-607. doi: 10.1586/erv.12.31. Abstract

Saitoh A, Okabe N. Recent progress and concerns regarding the Japanese immunization program: Addressing the "vaccine gap" Vaccine. 2014 Jul 23;32(34):4253-4258. Abstract

Saletti G, Gerlach T, Rimmelzwaan GF. Influenza vaccines: 'tailor-made' or 'one fits all'. Curr Opin Immunol. 2018 May 4;53:102-110. Abstract

Samson SI. et al. Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis. Expert Rev Vaccines. 2019 Jan 28. Abstract

Sano K. et al. Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics. Expert Rev Vaccines. 2018 Aug;17(8):687-696. Abstract

Sautto GA, Kirchenbaum GA, Ross TM. Towards a universal influenza vaccine: different approaches for one goal. Virol J. 2018 Jan 19;15(1):17. Full text

Scorza FB, Pardi N. New Kids on the Block: RNA-Based Influenza Virus Vaccines. Vaccines (Basel). 2018 Apr 1;6(2). pii: E20. Full text

Sebastian S, Lambe T. Clinical Advances in Viral-Vectored Influenza Vaccines. Vaccines (Basel). 2018 May 24;6(2). pii: E29. Full text

Sheldenkar A. et al.  Acceptance and uptake of influenza vaccines in Asia: A systematic review.  Vaccine. 2019 Aug 14;37(35):4896-4905. Full text

Shriver Z, Trevejo JM, Sasisekharan R. Antibody-Based Strategies to Prevent and Treat Influenza. Front Immunol. 2015 Jul 13;6:315. Full text

Skountzou I, Compans RW. Skin immunization with influenza vaccines. Curr Top Microbiol Immunol. 2015;386:343-69. Abstract

Soema PC. et al. Current and next generation influenza vaccines: Formulation and production strategies. Eur J Pharm Biopharm. 2015 Jun 3. pii: S0939-6411(15)00255-6. Full text

Song JM. Advances in novel influenza vaccines: a patent review. J Microbiol. 2016 Jun;54(6):403-12. Abstract

Sparrow E. et al. Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications. Vaccine. 2016 Sep 9. pii: S0264-410X(16)30744-7. Abstract

Tadount F, et al.  Is there a difference in the immune response, efficacy, effectiveness and safety of seasonal influenza vaccine in males and females? - A systematic review.  Vaccine. 2020 Jan 16;38(3):444-459.  Full text 

Tan J. et al. Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus? Curr Opin Immunol. 2018 Apr 17;53:45-50. Abstract

Tomar J. et al. Dry influenza vaccines: towards a stable, effective and convenient alternative to conventional parenteral influenza vaccination. Expert Rev Vaccines. 2016 May 21:1-17. Abstract

Treanor JJ. Prospects for Broadly Protective Influenza Vaccines. Am J Prev Med. 2015 Dec;49(6 Suppl 4):S355-63. Abstract

Tregoning JS, Russell RF, Kinnear E. Adjuvanted influenza vaccines. Hum Vaccin Immunother. 2017 Dec 12:0. Abstract

Trombetta CM, Gianchecchi E, Montomoli E. Influenza vaccines: Evaluation of the safety profile. Hum Vaccin Immunother. 2018 Jan 3:1-14. Abstract

Virk RK, Gunalan V, Tambyah PA. Influenza infection in human host: challenges in making a better influenza vaccine. (Singapore) Expert Rev Anti Infect Ther. 2016 Feb 17. Abstract

Wang TT, Bournazos S, Ravetch JV. Immunological responses to influenza vaccination: lessons for improving vaccine efficacy. Curr Opin Immunol. 2018 May 10;53:124-129. Abstract

Wang Y. et al. Universal influenza vaccines: from viruses to nanoparticles. Expert Rev Vaccines. 2018 Oct 26:1-10. Abstract

Wei CJ, et al. Next-generation influenza vaccines: opportunities and challenges. Nat Rev Drug Discov. 2020 Apr;19(4):239-252. Full text

Wong TM, Ross TM. Use of computational and recombinant technologies for developing novel influenza vaccines. Expert Rev Vaccines. 2015 Nov 23:1-11. Abstract

Xiang K. et al. Progress on adenovirus-vectored universal influenza vaccines. Hum Vaccin Immunother. 2015 Apr 15:0. Abstract

Young B. et al. The Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis and Meta-regression of Test-Negative Design Case-control Studies. J Infect Dis. 2017 Dec 6. Abstract

Valkenburg SA. et al. The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine. Front Immunol. 2018 Jul 2;9:1479. Full text

Zhang H, El Zowalaty ME. DNA-based influenza vaccines as immunoprophylactic agents toward universality. Future Microbiol. 2016 Jan;11:153-64. Abstract

Zhang N. et al. Advancements in the development of subunit influenza vaccines. Microbes Infect. 2015 Feb;17(2):123-34. Full text 

Zhao C, Xu J. Toward universal influenza virus vaccines: from natural infection to vaccination strategy. Curr Opin Immunol. 2018 Mar 28;53:1-6. Abstract

Zhou F. et al. Improving influenza vaccines: challenges to effective implementation. Curr Opin Immunol. 2018 Apr 29;53:88-95. Abstract

Zhu W, Wang C, Wang BZ. From Variation of Influenza Viral Proteins to Vaccine Development. Int J Mol Sci. 2017 Jul 18;18(7). pii: E1554. Full text